Matches in SemOpenAlex for { <https://semopenalex.org/work/W2912338581> ?p ?o ?g. }
Showing items 1 to 82 of
82
with 100 items per page.
- W2912338581 endingPage "S292" @default.
- W2912338581 startingPage "S292" @default.
- W2912338581 abstract "Patients with ulcerative colitis (UC) experience substantial impairment in quality of life (QOL), and QOL endpoints are therefore considered important measures of treatment outcome. We evaluated the effects of an investigational vedolizumab (VDZ) subcutaneous (SC) formulation on QOL and work productivity in VISIBLE 1 (NCT02611830; EudraCT 2015-000480-14), a Phase 3, placebo-controlled trial that demonstrated the efficacy and safety of VDZ SC in moderately to severely active UC. Following an open-label induction phase (VDZ intravenous [IV] 300 mg at Weeks 0 and 2), patients who achieved clinical response at Week 6 were randomised to maintenance phase treatment with: VDZ SC 108 mg every 2 weeks, VDZ IV 300 mg every 8 weeks, or the matching placebo (SC and IV). QOL was assessed using the Inflammatory Bowel Disease Questionnaire (IBDQ) and Euro Quality of Life-5D visual analogue scale (EQ-5D VAS), and work productivity using Work Productivity and Activity Impairment (WPAI-UC). Changes in QOL and work productivity from baseline (Week 0) to Week 52 and from Week 6 to Week 52 in the maintenance phase were compared between the three treatment groups using an analysis of covariance model (covariate: baseline score). There were 216 patients randomised at Week 6. Mean total IBDQ scores at Week 52 were: placebo, 135.2; VDZ SC, 180.7; VDZ IV, 170.7. Scores were significantly improved from baseline with both VDZ SC (+65.3) and VDZ IV (+58.6) compared with placebo (p < 0.001 for both) (Figure 1A). Mean EQ-5D VAS scores at Week 52 were: placebo, 58.1; VDZ SC, 76.1; VDZ IV, 71.4; change from baseline was significantly greater for VDZ SC (+27.1) and VDZ IV (+22.6) compared with placebo (p ≤ 0.001 for both) (Figure 1B). Similarly, improvements in mean WPAI-UC subscores were consistently greater with both VDZ SC and VDZ IV vs. placebo (Figure 1C). Improvements in IBDQ, EQ-5D VAS, and WPAI-UC scores observed at Week 6 were sustained through Week 52 with VDZ both VDZ SC and VDZ IV (Figure). Across all QOL and work productivity measures, patients who received maintenance placebo had substantial worsening in scores from Week 6 to Week 52 (Figure 1A–C). VDZ SC treatment was associated with overall significantly meaningful clinical improvements in IBDQ and EQ-5D VAS QOL instruments. Similarly, significant improvements in work productivity measures were observed among patients treated with VDZ SC. Further investigation of the effects of VDZ SC on QOL is needed to validate these findings. Figure 1. Changes in (A) IBDQ, (B) EQ-5D VAS, and (C) WPAI-UC scores from Week 0 to Week 52 and Week 6 to Week 52 in the three maintenance treatment groups." @default.
- W2912338581 created "2019-02-21" @default.
- W2912338581 creator A5019474609 @default.
- W2912338581 creator A5032150391 @default.
- W2912338581 creator A5045509681 @default.
- W2912338581 creator A5054781859 @default.
- W2912338581 creator A5068388301 @default.
- W2912338581 creator A5068806006 @default.
- W2912338581 creator A5074928602 @default.
- W2912338581 creator A5075986612 @default.
- W2912338581 date "2019-01-25" @default.
- W2912338581 modified "2023-10-11" @default.
- W2912338581 title "P374 Effects of subcutaneous vedolizumab on health-related quality of life and work productivity in patients with ulcerative colitis: results from the Phase 3 VISIBLE 1 trial" @default.
- W2912338581 doi "https://doi.org/10.1093/ecco-jcc/jjy222.498" @default.
- W2912338581 hasPublicationYear "2019" @default.
- W2912338581 type Work @default.
- W2912338581 sameAs 2912338581 @default.
- W2912338581 citedByCount "3" @default.
- W2912338581 countsByYear W29123385812023 @default.
- W2912338581 crossrefType "journal-article" @default.
- W2912338581 hasAuthorship W2912338581A5019474609 @default.
- W2912338581 hasAuthorship W2912338581A5032150391 @default.
- W2912338581 hasAuthorship W2912338581A5045509681 @default.
- W2912338581 hasAuthorship W2912338581A5054781859 @default.
- W2912338581 hasAuthorship W2912338581A5068388301 @default.
- W2912338581 hasAuthorship W2912338581A5068806006 @default.
- W2912338581 hasAuthorship W2912338581A5074928602 @default.
- W2912338581 hasAuthorship W2912338581A5075986612 @default.
- W2912338581 hasBestOaLocation W29123385811 @default.
- W2912338581 hasConcept C126322002 @default.
- W2912338581 hasConcept C139719470 @default.
- W2912338581 hasConcept C142724271 @default.
- W2912338581 hasConcept C159110408 @default.
- W2912338581 hasConcept C162324750 @default.
- W2912338581 hasConcept C1862650 @default.
- W2912338581 hasConcept C204787440 @default.
- W2912338581 hasConcept C204983608 @default.
- W2912338581 hasConcept C27081682 @default.
- W2912338581 hasConcept C2776207728 @default.
- W2912338581 hasConcept C2778260677 @default.
- W2912338581 hasConcept C2779134260 @default.
- W2912338581 hasConcept C2779951463 @default.
- W2912338581 hasConcept C2780479503 @default.
- W2912338581 hasConcept C2992962319 @default.
- W2912338581 hasConcept C71924100 @default.
- W2912338581 hasConceptScore W2912338581C126322002 @default.
- W2912338581 hasConceptScore W2912338581C139719470 @default.
- W2912338581 hasConceptScore W2912338581C142724271 @default.
- W2912338581 hasConceptScore W2912338581C159110408 @default.
- W2912338581 hasConceptScore W2912338581C162324750 @default.
- W2912338581 hasConceptScore W2912338581C1862650 @default.
- W2912338581 hasConceptScore W2912338581C204787440 @default.
- W2912338581 hasConceptScore W2912338581C204983608 @default.
- W2912338581 hasConceptScore W2912338581C27081682 @default.
- W2912338581 hasConceptScore W2912338581C2776207728 @default.
- W2912338581 hasConceptScore W2912338581C2778260677 @default.
- W2912338581 hasConceptScore W2912338581C2779134260 @default.
- W2912338581 hasConceptScore W2912338581C2779951463 @default.
- W2912338581 hasConceptScore W2912338581C2780479503 @default.
- W2912338581 hasConceptScore W2912338581C2992962319 @default.
- W2912338581 hasConceptScore W2912338581C71924100 @default.
- W2912338581 hasIssue "Supplement_1" @default.
- W2912338581 hasLocation W29123385811 @default.
- W2912338581 hasOpenAccess W2912338581 @default.
- W2912338581 hasPrimaryLocation W29123385811 @default.
- W2912338581 hasRelatedWork W2033059461 @default.
- W2912338581 hasRelatedWork W2097625012 @default.
- W2912338581 hasRelatedWork W2187503363 @default.
- W2912338581 hasRelatedWork W2586374020 @default.
- W2912338581 hasRelatedWork W2783252011 @default.
- W2912338581 hasRelatedWork W2794344940 @default.
- W2912338581 hasRelatedWork W2804630856 @default.
- W2912338581 hasRelatedWork W2912338581 @default.
- W2912338581 hasRelatedWork W2936289550 @default.
- W2912338581 hasRelatedWork W2947671916 @default.
- W2912338581 hasVolume "13" @default.
- W2912338581 isParatext "false" @default.
- W2912338581 isRetracted "false" @default.
- W2912338581 magId "2912338581" @default.
- W2912338581 workType "article" @default.